A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies.

Impairments in social relatedness and communication, repetitive behaviors, abnormal movement patterns, and sensory dysfunction characterize autism spectrum disorders (ASDs). Seventy consecutive patients with an ASD diagnosis (DSM-IV criteria, >/= 6 years-old) who presented to the Genetic Centers of America for outpatient genetic/developmental evaluations from 2005-2007 were examined. Patients were evaluated using CLIA-approved Laboratory Cooperation of America (LabCorp) testing for: serum testosterone, serum free testosterone, % free testosterone, serum/plasma dehydroepiandrosterone (DHEA), androstendione, and follicle-stimulating hormone (FSH). Morning blood samples collected following an overnight fast, compared to the pertinent reference means, showed significantly increased relative mean levels for: serum testosterone (158%), serum free testosterone (214%), percent free testosterone (121%), DHEA (192%), and androstenedione (173%). By contrast, compared to the pertinent reference mean, the relative mean level of FSH (51%) was significantly decreased. Additionally, at least one of the androgen attributes examined exceeded its recognized laboratory age- and sex-specific reference range in 81.4% (57 of 70) of the patients examined. With respect to their age- and sex-specific reference ranges, females had significantly higher overall mean relative testosterone and relative free testosterone levels than males. Increased androgens in patients diagnosed with ASDs may involve cyclical interactions between the androgen and the transsulfuration pathways, particularly following mercury exposure. A review of therapies that have significantly improved clinical outcomes in ASD patients indicates they share commonality in helping lower androgens. Thus, androgens should be routinely clinically measured in patients with an ASD diagnosis and appropriate androgen-lowering therapies considered for those who have significantly elevated levels.

[1]  David A Geier,et al.  A Case Series of Children with Apparent Mercury Toxic Encephalopathies Manifesting with Clinical Symptoms of Regressive Autistic Disorders , 2007, Journal of toxicology and environmental health. Part A.

[2]  T. Burbacher,et al.  Changes in the number of astrocytes and microglia in the thalamus of the monkey Macaca fascicularis following long-term subclinical methylmercury exposure. , 1996, Neurotoxicology.

[3]  H. Nakajima,et al.  A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group. , 1991, Endocrinologia japonica.

[4]  J. Carroll,et al.  Studies on a 3β3-hydroxysteroid sulphotransferase from rat liver , 1976 .

[5]  R. Lathe,et al.  Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. , 2006, Toxicology and applied pharmacology.

[6]  G. Dawson,et al.  Validation of the phenomenon of autistic regression using home videotapes. , 2005, Archives of general psychiatry.

[7]  A. Caufriez.  Menstrual disorders in adolescence: pathophysiology and treatment. , 1991, Hormone research.

[8]  R. Bhathena.  Therapeutic options in the polycystic ovary syndrome , 2007, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[9]  M. Hill,et al.  Plasma Thiols and Androgen Levels in Polycystic Ovary Syndrome , 2003, Clinical chemistry and laboratory medicine.

[10]  Rebecca C. Knickmeyer,et al.  Sex Differences in the Brain: Implications for Explaining Autism , 2005, Science.

[11]  Rebecca C. Knickmeyer,et al.  Androgens and autistic traits: A study of individuals with congenital adrenal hyperplasia , 2006, Hormones and Behavior.

[12]  R. Waring,et al.  Sulphur metabolism in autism. , 2000 .

[13]  G. Reynolds,et al.  The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat , 2007, Journal of psychopharmacology.

[14]  Toshiaki Tanaka,et al.  A Dose Finding Study of a Super Long-Acting Luteinizing Hormone-Releasing Hormone Analog (Leuprolide Acetate Depot, TAP-144-SR) in the Treatment of Central Precocious Puberty. , 1991 .

[15]  Bram P. Buunk,et al.  Second-to-fourth digit ratio related to verbal and numerical intelligence and the big five , 2005 .

[16]  R. A. Ryan,et al.  Studies on a 3beta-hydroxysteroid sulphotransferase from rat liver. , 1976, Biochimica et biophysica acta.

[17]  Abraham Weizman,et al.  Lowered DHEA-S plasma levels in adult individuals with autistic disorder , 2005, European Neuropsychopharmacology.

[18]  A. Zimmerman,et al.  Neuroglial activation and neuroinflammation in the brain of patients with autism , 2005, Annals of neurology.

[19]  G. B. Schaefer,et al.  Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders , 2006, Genetics in medicine : official journal of the American College of Medical Genetics.

[20]  Rebecca C. Knickmeyer,et al.  2nd to 4th digit ratios, fetal testosterone and estradiol. , 2004, Early human development.

[21]  Rebecca C. Knickmeyer,et al.  ‘Age of menarche in females with autism spectrum conditions ‘ , 2006, Developmental medicine and child neurology.

[22]  S. Baron-Cohen.  The extreme male brain theory of autism , 2002, Trends in Cognitive Sciences.

[23]  David W Gaylor,et al.  Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. , 2004, The American journal of clinical nutrition.

[24]  Inge-Marie Eigsti,et al.  A systems neuroscience approach to autism: biological, cognitive, and clinical perspectives. , 2003, Mental retardation and developmental disabilities research reviews.

[25]  H. Walach,et al.  Mercury and autism: accelerating evidence? , 2005, Neuro endocrinology letters.

[26]  David A. Geier,et al.  A prospective assessment of porphyrins in autistic disorders: A potential marker for heavy metal exposure , 2006, Neurotoxicity Research.

[27]  E. Giltay,et al.  Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  D. Geier,et al.  A Prospective Study of Mercury Toxicity Biomarkers in Autistic Spectrum Disorders , 2007, Journal of toxicology and environmental health. Part A.

[29]  J. Geleijnse,et al.  Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. , 2003, Atherosclerosis.

[30]  L. Ruble,et al.  Sexual Behaviors in Autism: Problems of Definition and Management , 1999, Journal of autism and developmental disorders.

[31]  K. A. Comer,et al.  Human liver steroid sulphotransferase sulphates bile acids. , 1990, The Biochemical journal.

[32]  R. Perry,et al.  Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. , 1984, The American journal of psychiatry.

[33]  R. DeFronzo,et al.  Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome , 2006, Clinical pharmacology and therapeutics.

[34]  S. Edelson,et al.  Effect of pioglitazone treatment on behavioral symptoms in autistic children , 2007, Journal of Neuroinflammation.

[35]  M. Aref-Adib,et al.  Risperidone for autism spectrum disorder. , 2007, The Cochrane database of systematic reviews.

[36]  R. Ferdinand,et al.  Differences in finger length ratio between males with autism, pervasive developmental disorder-not otherwise specified, ADHD, and anxiety disorders. , 2006, Developmental medicine and child neurology.

[37]  J T Manning,et al.  The 2nd to 4th digit ratio and autism , 2001, Developmental medicine and child neurology.

[38]  B. Nemeș,et al.  High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. , 2006, Life sciences.

[39]  K. Feingold,et al.  Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. , 2004, American journal of physiology. Endocrinology and metabolism.

[40]  Rebecca C. Knickmeyer,et al.  Elevated rates of testosterone-related disorders in women with autism spectrum conditions , 2007, Hormones and Behavior.

[41]  David A. Geier,et al.  A Clinical and Laboratory Evaluation of Methionine Cycle-Transsulfuration and Androgen Pathway Markers in Children with Autistic Disorders , 2006, Hormone Research in Paediatrics.

[42]  P. Roubertoux,et al.  Androgenic activity in autism. , 1997, The American journal of psychiatry.

[43]  V S Caviness,et al.  Brain asymmetries in autism and developmental language disorder: a nested whole-brain analysis. , 2004, Brain : a journal of neurology.

[44]  M. Maines,et al.  Alterations of heme, cytochrome P-450, and steroid metabolism by mercury in rat adrenal. , 1986, Archives of biochemistry and biophysics.

[45]  Julie Brown,et al.  Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. , 2009, The Cochrane database of systematic reviews.

[46]  Stepan Melnyk,et al.  Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[47]  S. Bölte,et al.  The Relation Between General Cognitive Level and Adaptive Behavior Domains in Individuals with Autism with and Without Co-Morbid Mental Retardation , 2002, Child psychiatry and human development.

[48]  J. Baio,et al.  Prevalence of Autism Spectrum Disorders: Autism and Developmental Disabilities Monitoring Network, United States, 2006. Morbidity and Mortality Weekly Report. Surveillance Summaries. Volume 58, Number SS-10. , 2009 .

[49]  H. Freeman,et al.  A study of the effects of methyl mercury, cadmium, arsenic, selenium, and a PCB, (aroclor 1254) on adrenal and testicular steroidogenesesin vitro, by the gray sealHalichoerus grypus , 1977, Archives of environmental contamination and toxicology.

[50]  Janet K. Kern,et al.  Evidence of Toxicity, Oxidative Stress, and Neuronal Insult in Autism , 2006, Journal of toxicology and environmental health. Part B, Critical reviews.

[51]  C. McDougle,et al.  Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. , 2003, Pediatrics.

[52]  L. Barregard,et al.  Endocrine function in mercury exposed chloralkali workers. , 1994, Occupational and environmental medicine.

[53]  Maurizio Elia,et al.  Sulphation deficit in “low-functioning” autistic children: a pilot study , 1999, Biological Psychiatry.

[54]  D. Geier,et al.  The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. , 2005, Medical hypotheses.

[55]  D. Geier,et al.  A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. , 2006, Neuro endocrinology letters.

[56]  W. McGinnis.  Oxidative stress in autism. , 2004, Alternative therapies in health and medicine.

[57]  D. Rossignol,et al.  Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders. , 2007, Medical hypotheses.

[58]  A. Chauhan,et al.  Oxidative stress in autism. , 2006, Pathophysiology : the official journal of the International Society for Pathophysiology.